Ursodeoxycholic acid in treatment of early cholestatic liver disease after allogeneic stem cell transplantation:report of 26 cases

CHEN Xin-chuan,LIU Ting,JIA Yong-qian,HE Chuan,LI Jian-jun,HUANG Jie

DOI: https://doi.org/10.3321/j.issn:1000-5404.2009.03.019

2009-01-01

Abstract:Objective To evaluate the effect of ursodeoxycholic acid(UDCA) in cholestatic liver disease at early stage in patients after allogeneic hematopoietic stem cell transplantation.Methods Twenty-six consecutive cases of cholestatic liver diseases after allogeneic hematopoietic stem cell transplantation were enrolled and randomly divided into 2 groups,the UDCA group(n=12) and the s-adenosyl methionine group(n=14).They received conventional pre-transplantation chemotherapy,and regular prevention and treatment for graft versus host disease.The patients of the UDCA group were taken UDCA tables at a dose of 14 mg·kg-1·d-1 for 14 d,and those out of the other group were intravenously infused with s-adenosyl methionine at a dose of 1 g/d for 14 d.Clinical evaluation and laboratory testing for alanine aminotransferases(ALT),aspartate aminotransferase(AST),alkaline phosphatase(ALP),gamma-glutamyl transpeptidase(GGT),total bilirubin(TBIL) and direct bilirubin(DBIL) were assessed pre-and post-treatment.TBIL reduced by ≥75%,≥50% or ≤50% were regarded as marked effective,effective or ineffective.Results At the end of the treatment,the 7/12 of patients treated with UDCA had gotten marked effective,the 3/12 gotten effective,whereas 3/12 ineffective.In the s-adenosyl methionine group,ratio of the 3 outcomes were 3/14,3/14 and 8/14 respectively.Compared with pre-therapy,there was a significant decrease in the serum ALT,ALP and GGT levels after treatment in both group(P<0.05).All patients completed their assigned treatment with no major adverse event.Conclusion UDCA therapy appears to be effective,safe and tolerable in individuals with cholestatic liver diseases in allogeneic hematopoietic stem cell transplantation.